enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 2.81M
Average 1.58M
ENGN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
enGene Holdings Inc.NASDAQ: ENGN
Financing Cash Flow · Q2 FY2026 · quarter ended Apr 2026
Financing cash flow dips below year-ago levels
Q2 FY2026 financing cash flow of $74K fell 62.8% year over year, behind the +136.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at -62.1% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -62.8% toward the trailing-twelve-month pace of +136.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 1.52M USD
- Year-over-year change
- -99.4%
- 4-year CAGR
- -49.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 1.52M | -99.4% |
| FY2024 | 2024-10-31 | 265.72M | +208.4% |
| FY2023 | 2023-10-31 | 86.15M | +208.0% |
| FY2022 | 2022-10-31 | 27.97M | +24.2% |
| FY2021 | 2021-10-31 | 22.53M | — |
Financing Cash Flow vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +136.8% is the 5th highest of 10, against a peer median of +127.8%.
- Over three fiscal years its annual growth of -62.1% compares with a peer median of +11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $365.04M USD | +52499.0% | +12.5% | — | |
| LTM Mar 2026 | $251.49M USD | +466.1% | +53.9% | 698594.4% | |
| LTM Mar 2026 | $173.2M USD | +64727.2% | -4.7% | — | |
| LTM Mar 2026 | $165.89M USD | +1517.0% | +11.1% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $143.06M USD | +136.8% | -62.1% | — |
| LTM Mar 2026 | $141.69M USD | +10.0% | -4.0% | — | |
| LTM Mar 2026 | $88.73M USD | +27.9% | +236.4% | 2309.3% | |
| LTM Mar 2026 | $17.39M USD | -123.8% | — | 25.5% | |
| LTM Mar 2026 | $2.59M USD | +127.8% | +75.3% | 1.2% | |
| LTM Dec 2025 | CHF 1.02M CHF | -9.0% | -10.2% | 28.5% | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
| Peer median (excluding ENGN) | — | +127.8% | +11.1% | 27.0% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (23.44M) | (24.46M) | (99.92M) | (55.14M) | (117.3M) |
| Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 435K | 116K | 3.45M | 5.32M | 9.65M |
| Change in Working Capital | (1.04M) | 2.17M | (517K) | 95K | 9.74M |
| Accounts Receivables | 295K | 143K | (1.01M) | 2.01M | (595K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 110K | (197K) | 373K | 474K | 4.94M |
| Other Working Capital | (1.44M) | 2.23M | 117K | (2.39M) | 5.39M |
| Other Non-Cash Items | 7.79M | 4.34M | 72.07M | 1.12M | (1.83M) |
| Operating Cash Flow | (15.98M) | (17.59M) | (24.74M) | (48.28M) | (99.24M) |
| Capital Expenditures | (248K) | (153K) | (318K) | (925K) | (1.49M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (125.03M) | (160.84M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 137.19M |
| Other Investing Activities | 1K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (247K) | (153K) | (318K) | (125.95M) | (25.14M) |
| Debt Repayment | 7.07M | 28.39M | 33.27M | 13.06M | (699K) |
| Common Stock Issued | 14K | 12K | 56.89M | 260.15M | 2.22M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (144K) | (423K) | (4.01M) | (7.49M) | 0 |
| Financing Cash Flow | 22.53M | 27.97M | 86.15M | 265.72M | 1.52M |
| Effect of Forex Changes | 98K | (805K) | 1K | 1K | 1K |
| Net Change in Cash | 6.39M | 9.42M | 61.09M | 91.48M | (122.85M) |
| Free Cash Flow | (16.23M) | (17.75M) | (25.06M) | (49.21M) | (100.72M) |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.